Slingshot Insights | Iphyf Overview

IPHYF Overview

Upcoming Projects (IPHYF)

Don’t see a project related to the company you care about? Create your own!

Upcoming & Overdue Catalysts (IPHYF)

Don’t see a catalyst related to the company you care about? Create your own!

Occurred Catalysts (IPHYF)

Safety of the first-in-class anti-NKG2A monoclonal antibody monalizumab in combination with cetuximab: a phase Ib/II study in recurrent or metastatic squamous cell carcinoma of the head and neck expected April 5 2017
Ticker: IPHYF
Occurred on: Apr 05, 2017
NKG2A checkpoint receptor expression on tumor-infiltrating CD8+ T cells restrains efficacy of immunotherapy data expepcted April 3 2017
Ticker: IPHYF
Occurred on: Apr 03, 2017
Bristol-Myers Squibb (BMY) Fails Phase 2 EkkiKIR Trial Evaluating Innate Pharma's (IPHYF) Lirilumab in Treatment of Acute Myeloid Leukemia (AML)
Tickers: BMY, IPHYF
Occurred on: Feb 06, 2017
Phase I study initiated for durvalumab in combination with monalizumab in patients with solid tumors
Ticker: IPHYF
Occurred on: Feb 08, 2016

Strategic Initiatives (IPHYF)

Don’t see a strategic initiative related to the company you care about? Create your own!